Review On: Computational Aided Drug Design for Polyherbal Formulations

Abstract

Polyherbal formulations are widely used in traditional medicine because they combine multiple botanicals to improve therapeutic efficacy, broaden biological coverage, and potentially reduce toxicity compared with single-herb preparations . However, their scientific development is constrained by multicomponent complexity, uncertain mechanisms, variable phytochemical profiles, and the difficulty of selecting optimal herb ratios. Computational aided drug design (CADD) offers a practical way to address these limitations by enabling virtual screening, molecular docking, pharmacophore modeling, network pharmacology, and synergy prediction before experimental validation . In recent years, machine learning-based approaches have expanded rapidly and are increasingly used to predict synergistic drug combinations from high-throughput data . For polyherbal systems, these tools can prioritize bioactive compounds, identify multi-target interactions, and support formulation optimization. This review discusses the conceptual basis of synergy in polyherbal medicine, outlines major CADD strategies applicable to herbal formulations, and examines computational methods for synergy prediction. It also highlights the role of systems biology and artificial intelligence in advancing evidence-based herbal drug development. Finally, the review addresses limitations such as data standardization, model interpretability, and translational barriers, while proposing future directions for precision herbal medicine.

Introduction

This review examines the application of Computer-Aided Drug Design (CADD) in the development of polyherbal formulations, which combine two or more herbs to achieve enhanced therapeutic effects. In traditional systems such as Ayurveda, herbs are deliberately combined so that different ingredients can act through complementary mechanisms, improving efficacy, absorption, stability, and metabolism. Such formulations are particularly useful for treating complex diseases involving multiple biological pathways. However, the presence of numerous phytochemicals and their complex interactions makes scientific evaluation challenging, creating a need for computational approaches that can efficiently predict and analyze herbal combinations.

A central concept in polyherbal medicine is synergy, where the combined effect of multiple herbs is greater than the sum of their individual effects. Synergy may be pharmacodynamic, involving action on different targets or pathways within the same disease process, or pharmacokinetic, where one component enhances the absorption, distribution, metabolism, or elimination of another. Modern research emphasizes measuring synergy rather than assuming it, using mathematical models such as Bliss Independence, Loewe Additivity, Highest Single Agent (HSA), and Zero Interaction Potency (ZIP) to distinguish true synergistic effects from simple additive effects.

The review highlights several important CADD strategies used in herbal research. Structure-based drug design utilizes the three-dimensional structures of target proteins to assess how phytochemicals bind to biological targets through molecular docking. Ligand-based drug design is applied when target structures are unavailable, using known active compounds to develop pharmacophore models, similarity searches, and quantitative structure–activity relationship (QSAR) models. Virtual screening enables rapid evaluation of large phytochemical libraries, helping identify promising compounds while filtering out those with poor pharmacokinetic or toxicity profiles.

A particularly important approach for herbal medicine is network pharmacology, which reflects the multi-component and multi-target nature of polyherbal formulations. Network pharmacology maps relationships among phytochemicals, biological targets, signaling pathways, and diseases to reveal key mechanisms of action. This approach helps explain how multiple herbs can work together in diseases such as cancer, diabetes, inflammation, and metabolic disorders, where single-target therapies may be insufficient. However, its effectiveness depends heavily on the quality and completeness of available biological databases.

The review also discusses synergy prediction, an emerging field that combines classical synergy models with machine learning techniques. While traditional models provide interpretable measures of synergistic interactions, machine learning and deep learning methods can analyze chemical structures, gene expression patterns, and biological response data to predict effective herbal combinations before experimental testing. These methods may eventually support optimized formulation design by identifying ideal herb combinations and dosage ratios.

Artificial Intelligence (AI) and Machine Learning (ML) are increasingly influencing herbal drug discovery. AI can predict biological activity, toxicity, pharmacokinetic behavior, and molecular targets directly from chemical structures. It can also optimize formulation compositions using algorithms such as neural networks and genetic algorithms. However, the review emphasizes that AI remains limited by incomplete herbal databases and should be viewed as a decision-support tool rather than a substitute for laboratory research.

Validation and standardization are identified as critical requirements for successful polyherbal drug development. Computational predictions must be verified through in vitro studies, in vivo experiments, and clinical trials. Standardization of plant materials, extraction methods, compound libraries, and target databases is necessary to ensure reproducibility and regulatory acceptance. Computational tools can support quality control and mechanism-of-action studies but cannot replace safety testing and clinical evaluation.

Looking ahead, the review suggests that the future of polyherbal formulation design will depend on integrating multiple computational approaches, including molecular docking, network pharmacology, machine learning, and AI. Emerging areas such as multi-omics integration (transcriptomics, proteomics, metabolomics, and microbiome analysis), personalized herbal medicine, quantum-inspired modeling, and hybrid AI workflows are expected to improve understanding of complex herbal systems. The authors conclude that combining computational prediction with rigorous experimental validation offers a rational and efficient pathway for developing evidence-based, safe, and effective polyherbal medicines.

Conclusion

Computational aided drug design provides a strong framework for rational polyherbal formulation development . It can help identify active compounds, map targets, predict synergy, and prioritize combinations for experimental testing. This is especially useful in traditional medicine, where formulas contain many ingredients and the mechanism of action is often unclear . The central value of CADD is that it transforms polyherbal research from an empirical process into a more evidence-based one. Synergy prediction, network pharmacology, and machine learning can improve formulation design, but only when supported by good data and experimental validation . For researchers developing herbal syrups, creams, or other dosage forms, this approach offers a practical and modern path toward scientifically validated products.

References

[1] Aladejana, E. B. (2023). Biological properties of polyherbal formulations: A review of their antimicrobial, anti-inflammatory, antioxidant, and toxicological activities. Pharmacognosy Journal, 15(5), 933–963. [2] Abbasi, F., & Rousu, J. (2025). New methods for drug synergy prediction: A mini-review. Trends in Pharmacological Sciences. [3] Current perspectives and trend of computer-aided drug design: A review and bibliometric analysis. (2024). PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC11175770/ [4] Computer-Aided Drug Design and Drug Discovery. (2023). PMC NIH. https://pmc.ncbi.nlm.nih.gov/articles/PMC10819513/ [5] Computer Aided Drug Design Methodologies with Natural Products. (2022). PMC NIH. https://pmc.ncbi.nlm.nih.gov/articles/PMC9881095/ [6] Computer-Aided Drug Design Methods. (2016). PMC NIH. https://pmc.ncbi.nlm.nih.gov/articles/PMC5248982/ [7] Madhuri, L. G., Vaishnavi, P. A., Anekar, M., & Patil, M. S. (2023). Computer aided drug design: An overview. International Journal of Pharmaceutical and Preventive Research, 14(2), 69–78. [8] Naik, Y., & Goudanavar, S. (2025). Quantum-inspired computational drug design for phytopharmaceuticals: A herbal holography analysis. Journal of Molecular Modeling, 31(7), 188. https://doi.org/10.1007/s00894-025-06412-w [9] Navami, U., Divya Jyothi, Nireeeksha Shetty, & Nisha N Shetty. (2024). Design and optimization of polyherbal gels for topical drug delivery by central composite statistical design. Research Journal of Pharmacy and Technology, 17(12), 5702–5706. https://doi.org/10.52711/0974-360X.2024.00868 [10] Saini, J., & Parashar, M. (2025). Development and evaluation of polyherbal dispersible tablets using aqueous leaf extracts. Journal of Pharmaceutical Research International, 37(4), 79–86. https://doi.org/10.9734/jpri/2025/v37i47680 [11] Zhang, X., Liu, Y., & Wang, H. (2024). Integrative network pharmacology, molecular docking, and dynamic simulation analysis of a polyherbal formulation for potential therapeutic impact on prostate cancer. Heliyon, 10(14), e34531. https://doi.org/10.1016/j.heliyon.2024.e34531 [12] Polyherbal formulation concept for synergic action: A review. (2019). Journal of Drug Delivery and Therapeutics, 9(1-s), 123–130. https://doi.org/10.22270/jddt.v9i1-s.2339 [13] Synergistic effect of polyherbal extract containing indigenous medicinal plants. (2025). Applied Journal of Alternative and Integrative Medicine. [14] Synergistic effects of phytochemicals in polyherbal formulations. (2025). International Journal of Pharmaceutical Sciences Research. [15] Drug synergy prediction – TDC. (2024). Therapeutics Data Commons. https://tdcommons.ai/multi_pred_tasks/drugsyn/ [16] Computational methodology for drug discovery. (2024). Nature Collections. https://www.nature.com/collections/dhcgiaigac [17] AI-driven drug discovery: A comprehensive review. (2025). ACS Omega. https://doi.org/10.1021/acsomega.5c00549 [18] AI in ethnopharmacology, the pharmaceutical industry, and its applications. (2025). Annales Pharmaceutiques Françaises. https://doi.org/10.1016/j.pharma.2025.11.011 [19] Artificial intelligence (AI) applications in drug discovery and development. (2024). PMC NIH. https://pmc.ncbi.nlm.nih.gov/articles/PMC11510778/ [20] Computational frameworks transform antagonism to synergy in optimizing drug combinations. (2025). Nature Digital Medicine. https://doi.org/10.1038/s41746-025-01435-2 [21] MD-Syn: Synergistic drug combination prediction based on a multidimensional feature fusion method and attention mechanisms. (2025). Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2025.1564339 [22] A systematic evaluation of deep learning methods for the prediction of drug synergy. (2023). PLoS Computational Biology, 19(3), e1010200. https://doi.org/10.1371/journal.pcbi.1010200 [23] Systematic review of computational methods for drug combination prediction. (2022). Computational and Structural Biotechnology Journal, 20, 2807–2814. https://doi.org/10.1016/j.csbj.2022.05.055 [24] Network pharmacology and molecular docking approaches for herbal formulations: Mechanistic insights, therapeutic applications, and translational perspectives. (2026). International Journal of Pharma and Bio Sciences, 17(1), 24–33. https://doi.org/10.22376/ijpbs.v17i1.142 [25] Quantum computing in molecular design and drug discovery. (2026). Journal of ISI, 8(1). https://doi.org/10.63158/journalisi.v8i1.1380 [26] AI-enabled computational strategies in herbal drug discovery. (2026). International Journal of Ayurveda, Herbal Medicine and Integrative Medicine. [27] Advances in drug design: A review of recent trends, challenges and future scope. (2025). Quarterly Journal of Medicine and Health Sciences. [28] A review on drug design: Strategies, advances, and future directions. (2025). International Journal of Applied Science and Engineering Technology. [29] Drug design—Past, present, future. (2022). PMC NIH. https://pmc.ncbi.nlm.nih.gov/articles/PMC8911833/ [30] Research in the field of drug design and development. (2023). PMC NIH. https://pmc.ncbi.nlm.nih.gov/articles/PMC10536713/

Copyright

Copyright © 2026 Miss. Asmita D Tengle , Miss. Ketakee R. More, Dr. Nitin M Gawai, Miss. Sayali R Bhalsen, Miss. Vaidehi V Tukurul . This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.